{"id":837433,"date":"2025-04-15T08:58:24","date_gmt":"2025-04-15T12:58:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/"},"modified":"2025-04-15T08:58:24","modified_gmt":"2025-04-15T12:58:24","slug":"vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/","title":{"rendered":"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity"},"content":{"rendered":"

\nOver half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans
\n<\/h2>\n
\n

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc.<\/a> (NASDAQ: VANI<\/a>) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc.<\/a> (“Okava”), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions. Vivani and Okava initiated their collaboration in 2019, with a focus on developing OKV-119 for cardiometabolic conditions in cats.<\/p>\n

OKV-119 leverages Vivani\u2019s proprietary NanoPortal\u2122 technology, which provides smooth and steady delivery of therapeutic molecules, including GLP-1 receptor agonists, over extended periods from a single implant. According to Okava, dosing every six months or longer supports a \u201cOne-and-Done\u201d approach between office visits consistent with the product profile of Vivani\u2019s NPM-115, an ultra long-acting GLP-1 implant in clinical stage development to improve medication adherence and tolerability for the treatment of chronic weight management in humans.<\/p>\n

“Caloric restriction, or fasting, is one of the most well-established interventions for extending the lifespan and improving metabolic health in dogs,” said Okava CEO Michael Klotsman, PhD, MBA. “But it is also one of the hardest to maintain. OKV-119 mimics many of the physiological effects of fasting\u2014improved insulin sensitivity, reduced fat mass and more efficient energy metabolism\u2014without requiring significant changes in feeding routines or disrupting the human-animal bond that often centers around food.”<\/p>\n

Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic disease, metabolic decline and shortened lifespans. Similar to the changes humans face as they grow older, aging dogs experience declines in metabolic fitness, leading to weight gain, insulin resistance and loss of muscle mass. Research shows that leaner dogs can live more than two years longer than their heavier counterparts. By restoring and maintaining a healthy metabolism through a single, long-acting dose, OKV-119 has the potential to enhance quality of life, promote healthy aging and become the most impactful life-extending therapy available for dogs.<\/p>\n

“This collaboration aligns with Vivani\u2019s broader mission to develop innovative medicines that will revolutionize the treatment of chronic diseases by leveraging proprietary drug delivery technologies,” said Vivani CEO Adam Mendelsohn, PhD. “This expanded partnership with Okava reflects our shared confidence in the potential of NanoPortal technology to serve a broad array of prospective beneficiaries in the management of metabolic disease. The structure of this expanded partnership minimizes costs and risks for Vivani while integrating upside potential for Vivani shareholders through future milestone payments and royalties. Together with Okava, we are broadening the reach of our technology, meeting unmet needs in veterinary medicine while positioning Vivani to capture future value within an industry segment experiencing continued and unprecedented growth.”\u00a0\u00a0<\/p>\n

Financial terms of the expanded agreement were not disclosed.<\/p>\n

\n About Vivani Medical, Inc.<\/strong>\n <\/p>\n

Leveraging its proprietary NanoPortal platform, Vivani develops therapeutic implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani\u2019s lead programs, NPM-139 (semaglutide implant) and NPM-115 (exenatide implant), are miniature, subdermal GLP-1 implants under development for chronic weight management in obese or overweight individuals designed for once or twice-yearly administration. Vivani\u2019s emerging pipeline also includes NPM-119, which refers to the Company\u2019s six-month, subdermal, GLP-1 (exenatide implant) under development for the treatment of type 2 diabetes. Development of a semaglutide implant for the treatment of type 2 diabetes is also under consideration. These NanoPortal implants are designed to provide patients with the opportunity to experience the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of oral and injectable medications.<\/p>\n

Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason why obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments, face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature, ultra long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers. For more information, please visit:\u00a0www.vivani.com<\/a>.<\/p>\n

\n About Okava Pharmaceuticals, Inc.<\/strong>\n <\/p>\n

OKAVA is a clinical-stage research and development company that develops new treatment options for dogs and cats suffering from chronic diseases of aging. OKAVA is building a portfolio of products to transform and humanize standards of care in veterinary medicine. By harnessing human technologies for the treatment of common diseases in household pets, the company has the potential of increasing the lifespans of dogs and cats by an average of 1 to 3 years. OKAVA is a private company headquartered in San Francisco, California. For more information, see www.okava.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains certain \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: \u201ctarget,\u201d \u201cfuture,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cwould,\u201d \u201cpositioned,\u201d and other similar expressions that in this press release, including statements regarding Vivani\u2019s business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the ongoing clinical trial and reporting of trial results, Vivani\u2019s emerging development plans for its products, Vivani\u2019s collaboration agreement with Okava, and Vivani\u2019s technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani\u2019s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani\u2019s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani\u2019s products; delays and changes in the development of Vivani\u2019s products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani\u2019s development activities; risks related to the initiation, enrollment and conduct of Vivani\u2019s planned clinical trials and the results therefrom; Vivani\u2019s history of losses and Vivani\u2019s ability to access additional capital or otherwise fund Vivani\u2019s business; market conditions and the ability of Cortigent to complete its intended spin-off from the Company. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC filed on March 31, 2025, as updated by the Company\u2019s subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.<\/p>\n

\n Vivani Contacts:<\/strong>\n <\/p>\n

Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com<\/a>
(415) 506-8462<\/p>\n

Investor Relations Contact:
Jami Taylor
Investor Relations Advisor
investors@vivani.com<\/a>
(415) 506-8462<\/p>\n

Media Contact:
Sean Leous
ICR Healthcare
Sean.Leous@ICRHealthcare.com<\/a>
(646) 866-4012<\/p>\n

\n Okava Contacts:<\/strong>\n <\/p>\n

Investor Relations Contact:
Jami Taylor
Investor Relations Advisor
pr@okava.com<\/a>
(415) 506-8462<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc. (“Okava”), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions. Vivani and Okava initiated their collaboration in 2019, with a focus on developing OKV-119 for cardiometabolic conditions in cats. … <\/p>\n

Continue reading “Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837433","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc. (“Okava”), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions. Vivani and Okava initiated their collaboration in 2019, with a focus on developing OKV-119 for cardiometabolic conditions in cats. … Continue reading "Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T12:58:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity\",\"datePublished\":\"2025-04-15T12:58:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/\"},\"wordCount\":1370,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/\",\"name\":\"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA=\",\"datePublished\":\"2025-04-15T12:58:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/","og_locale":"en_US","og_type":"article","og_title":"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity - Market Newsdesk","og_description":"Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc. (“Okava”), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions. Vivani and Okava initiated their collaboration in 2019, with a focus on developing OKV-119 for cardiometabolic conditions in cats. … Continue reading \"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-15T12:58:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity","datePublished":"2025-04-15T12:58:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/"},"wordCount":1370,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/","name":"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA=","datePublished":"2025-04-15T12:58:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjM3MCM2ODY2MjY3IzIyOTkzOTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabolic-health-and-longevity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837433"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837433\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}